In January, the owner of a general dental practice collecting $3.0M closed the books on his best year. Collections up 9%, case acceptance strong, the new implant workflow finally paying for the CBCT. In March, after a first conversation with a DSO's development team, the analyst's data request arrived. It asked for production by procedure code, by provider, by month, three years back. Before the P&L. Before the tax returns. The code-level file was the first thing the buyer wanted, and the owner had never once looked at his practice through it. The practice is a composite drawn from engagement work; the math below is the math the code file produced.
The number the owner trusted was the growth rate. Collections up 9% reads as a practice getting more valuable, and every month of the year the total confirmed it. The code file sorts the same dollars by a property the P&L doesn't record: whether a dollar of this year's revenue renews itself next year or has to be sold again from zero. A hygiene dollar arrives with its own replacement booked, because the reappointment happens before the patient leaves the chair. An implant dollar completes and disappears, and next year's implant dollar must be originated all over again, from a new patient, a new diagnosis, a new financing approval. The buyer reads the growth rate the way the owner does only after checking which kind of dollar produced it.
Two practices, one top line
Take two general practices, each collecting $3.0M. Composite figures, rounded, and the structure survives any reasonable substitution.
Practice A built its growth on large-case dentistry. Hygiene produces $600K, 20% of the top line and well under the 30 to 33% band the practice-management benchmarks treat as the mark of a healthy recall engine. Restorative work flowing out of those hygiene chairs produces $1,200K. Elective large-case work, implants, full-arch, clear aligners, produces the remaining $1,200K, and that is the line the 9% growth landed on. It's also the line the owner is proudest of. The CBCT, the surgical guides, the two implant courses in Scottsdale: that line took real clinical investment to build, which is part of why nobody in the practice thinks of it as the fragile one.
Practice B built its growth on recall density. Hygiene $960K, 32% of the same top line. Recall-driven restorative $1,560K. Elective $480K.
Now apply the renewal character of each line, the analyst's move. Say the active recall base returns at 95%, restorative diagnosed out of those chairs recurs at 90% as the base cycles through, and completed elective cases are replaced at 40%, because each one ends and the next must be created from new demand. Composite rates, and directionally what a buyer will model.
Practice A: $600K x 0.95 is $570K. $1,200K x 0.90 is $1,080K. $1,200K x 0.40 is $480K. Revenue that renews itself: $2,130K. Revenue that must be re-sold next year: $870K, 29% of the practice.
Practice B: $960K x 0.95 is $912K. $1,560K x 0.90 is $1,404K. $480K x 0.40 is $192K. Renewing: $2,508K. Re-sold: $492K, about 16%.
Same collections. Same growth rate, if you like.
One practice starts every January owing itself $870K of demand it has to create before it grows a dollar.
The other owes itself $492K. The gap between them appears on no statement either practice produces, and it is the first thing the code file shows the buyer.
Why the shapes diverge
The recall dollar is behaviorally contracted. The reappointment is made in the operatory, six months out, before the patient has re-entered the decision to buy. Nothing about a completed implant case books its successor. Every elective dollar is re-originated: a new exam, a new case presentation, a new yes, and increasingly a new financing approval. One line runs on a standing order. The other runs on a sales process that resets to zero at every completion.
The elective line is also the cyclical one. Large-case dentistry is discretionary spend, sensitive to rates, financing appetite, and consumer confidence, which means the line carrying Practice A's growth is the line most exposed to conditions nobody in the practice controls. FOCUS Investment Banking's 2026 valuation work states the buyer's side of this plainly: a large share of dental EBITDA comes from routine hygiene visits, and buyers pay premiums for practices whose forward cash flows are anchored there, because that revenue arrives on its own. The premium for the recall-anchored practice and the discount for the case-driven one are the same adjustment, seen from two sides.
And the treadmill speeds up as it succeeds. When the elective line grows 15%, next year's re-sold obligation grows with it. Practice A's best growth year raised its January debt to $870K. A practice can grow its top line and grow its fragility in the same motion, and the monthly production report will record only the first.
The re-sold share
Call it the re-sold share: the fraction of this year's collections that must be created again next year from new demand. The practice software already holds everything required, production by code is a standard report, and the classification on top of it takes an afternoon. Sort every code into renewing and re-sold, weight by the recall return rate the practice already tracks, and the number falls out. The owner's reporting shows collections by month and production by provider. It has no column for renewal character, which is why a 9% growth year can quietly raise the re-sold share from 24% to 29% without anyone deciding to become a more fragile practice. The buyer's QoE team will compute this in the first week of diligence. The owner can compute it first, while there's still time to move it, or read it for the first time inside someone else's model.
Which line the growth lands on
The owner arrived asking what the growth was worth. That was the wrong question, because the growth was two different kinds of dollar reported as one total. The governing question is which line the growth lands on, and whether the re-sold share is rising or falling as the practice expands. A growth plan that adds recall density compounds; a growth plan that adds case volume rents. This is Stage 1 work in RIDA, the proprietary economic discipline B.L. Sheets & Co. runs on: revenue is decomposed by renewal character before any growth or exit conversation starts, because every later decision, the associate hire, the marketing spend, the LOI response, prices differently depending on which kind of dollar it touches.
For the owner eighteen months from a sale, the sequence writes itself. Pull the code file the buyer will pull. Compute the re-sold share. Then spend the window moving growth onto the lines that renew, because the buyer will pay for the first and discount the second.
A buyer prices the revenue that returns on its own. Everything else, you sold once.
This essay describes general transaction structure. It is not legal advice, not a valuation, and not investment advice. Figures drawn from published sources are cited in the text; illustrative case figures are composites and describe no identifiable practice or firm.
Sources. FOCUS Investment Banking, Dental Practice Valuation for 2026, on hygiene-driven EBITDA and buyer premiums for recall-anchored forward cash flows. Dentistry IQ and Inspired Hygiene on the 30 to 33% hygiene production benchmark; the Academy of Dental CPAs ranges corroborate at 30 to 40%. Precision Dental Analytics on QoE analysis as the institutional buyer's primary diligence tool. Both practices in the demonstration are composites drawn from engagement work, and their figures, including the renewal rates, are labeled as such in the text.
← More from The Decision Layer